At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 169 enrolled
Drug / intervention
VVN001 Ophthalmic Solution 1% +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Double-Masked, Randomized, Vehicle-controlled Trial Evaluating the Safety and Efficacy Activity of 1% and 5% VVN001 Compared to Vehicle in Subjects With Dry Eye Disease
In Brief
A Phase 2 clinical trial evaluating VVN001 Ophthalmic Solution 1%, VVN001 Ophthalmic Solution 5%, and 1 other intervention for Dry Eye. Completed, enrolled 169 participants across 1 site.
Detailed Summary
This is a Phase 2a, multi-center, double-masked, randomized, vehicle-controlled, parallel-group study designed to evaluate the safety and tolerability and to explore the efficacy activity of VVN001 ophthalmic solution versus vehicle in subjects with dry eye disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedSep 2020
Enrollment StartDec 2020
Primary CompletionDec 2021
TodayJul 2026
First PostedSep 21, 2020
Enrollment StartDec 3, 2020
Primary CompletionDec 1, 2021
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 5.8 years ago
Interventions
VVN001 Ophthalmic Solution 1%drug
VVN001 Ophthalmic Solution 1%
VVN001 Ophthalmic Solution 5%drug
VVN001 Ophthalmic Solution 5%
Vehicledrug
VVN001 Ophthalmic Solution Vehicle